Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors.
Yue ChengLowell AnthonyChris DelcherDaniela C MogaAman ChauhanBin HuangVal AdamsPublished in: The oncologist (2023)
Octreotide LAR dosing above the label-maximum dose is common and IR rescue dosing appears to be underutilized.